Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)
FMS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FMS
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases by publicly reported revenue, offering dialysis services, value-based care programs, and a broad portfolio of renal healthcare products [sec · filed 2026-08-04].
Key risk: Reimbursement rate dependency
Market Cap
$12.29B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2018.
Tracking 18 clinical trials for Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share).
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases by publicly reported revenue, offering dialysis services, value-based care programs, and a broad portfolio of renal healthcare products [sec · filed 2026-08-04].
- World's leading provider of products and services for renal diseases based on publicly reported revenue [sec · filed 2026-08-04].
- Approximately 78% of revenue for the six months ended June 30, 2026 came from healthcare services (including insurance services) [sec · filed 2026-08-04].
- Same Market Treatment Growth in the U.S. was (0.9%) and (0.6%) for the three and six months ended 2026, negatively impacted by transformation activities [sec · filed 2026-08-04].
- Company is assessing the impact of GLP-1 receptor agonists and SGLT2 inhibitors on CKD and ESRD populations, with current models suggesting a balanced effect [sec · filed 2026-08-04].
- Net cash used in financing activities was €1,206 M in the first six months of 2026, mainly for debt repayment, share buybacks, and dividends [sec · filed 2026-08-04].
What works
- Market leadership in renal disease products and services provides a strong competitive position [sec · filed 2026-08-04].
- Diversified revenue stream with 78% from healthcare services and the remainder from product sales [sec · filed 2026-08-04].
- Ongoing analysis of GLP-1 and SGLT2 drug impacts suggests no material adverse change to patient population forecasts currently [sec · filed 2026-08-04].
What to weigh
- Same Market Treatment Growth in the U.S. declined due to disruptions from organizational redesign and clinic footprint optimization [sec · filed 2026-08-04].
- Profitability is significantly dependent on reimbursement rates for services [sec · filed 2026-08-04].
- Exposed to cost increases and supply chain impacts from geopolitical conflicts, including the Middle East [sec · filed 2026-08-04].
- Potential for new pharmaceuticals (e.g., GLP-1s, SGLT2s) to reduce ESRD population growth, though current models show balanced effect [sec · filed 2026-08-04].
From the filings
Quoted directly from source documents.
Company is the world leader in renal disease products and services by revenue.
“We are the world's leading provider of products and services for individuals with renal diseases, based on publicly reported revenue.”
SEC filings · August 4, 2026
78% of revenue came from healthcare services in the first half of 2026.
“For the six months ended June 30, 2026, approximately 78% of our revenue was generated by providing healthcare services (including insurance services), a major po”
SEC filings · August 4, 2026
U.S. Same Market Treatment Growth was negative due to transformation disruptions.
“Same Market Treatment Growth in the U.S. of (0.9%) and (0.6%) for the three and six months ended 2026, respectively, were negatively impacted by disruptions from broad-based transformation activities”
SEC filings · August 4, 2026
GLP-1 and SGLT2 drugs currently show a balanced effect on patient populations.
“the Company sees a balanced effect of the drugs on the patient population”
SEC filings · February 24, 2026
Risks & what to watch (4)›
Key risks
- Reimbursement rate dependency — Profitability depends significantly on reimbursement rates for services [sec · filed 2026-08-04].
- Transformation disruption — Organizational redesign and clinic footprint optimization negatively impacted patient inflow [sec · filed 2026-08-04].
- Geopolitical supply chain risks — Cost increases and supply chain impacts from Middle East conflict [sec · filed 2026-08-04].
- New drug competition — GLP-1 and SGLT2 inhibitors may reduce ESRD population growth, though current models show balanced effect [sec · filed 2026-08-04].
What to watch
- Impact of GLP-1 and SGLT2 inhibitor utilization on CKD and ESRD patient populations [sec · filed 2026-08-04].
- Progress of FME25+ Program and its effect on cost savings and growth [sec · filed 2026-05-05].
- Reimbursement rate changes for dialysis services [sec · filed 2026-08-04].
- Outcome of litigation and government investigations [sec · filed 2026-08-04].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
214
Total value held
$913.2M
| Holder | Shares | Value |
|---|---|---|
| pzena investment management llc | 15,052,822 | $339.6M |
| fiduciary management inc /wi/ | 4,462,106 | $100.7M |
| dodge & cox | 3,826,910 | $86.3M |
| morgan stanley | 2,484,810 | $56.1M |
| millennium management llc | 1,641,301 | $37.0M |
| brandes investment partners, lp | 1,610,849 | $36.3M |
| todd asset management llc | 1,296,543 | $29.3M |
| goldman sachs group inc | 818,002 | $18.5M |
| blackrock, inc. | 627,669 | $14.2M |
| point72 asset management, l.p. | 509,907 | $11.5M |
Showing top 10 of 214 institutional holders of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share). Open the full 13F history after sign-in.
Frequently asked questions
What is the AI investment thesis for Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)?
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases by publicly reported revenue, offering dialysis services, value-based care programs, and a broad portfolio of renal healthcare products [sec · filed 2026-08-04].
Who is the CEO of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)?
Ms. Helen Giza is the chief executive officer of Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS).
Where is Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) headquartered?
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS) is headquartered in Bad Homburg, Germany.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.